Coramaze Technologies develops the Tripair, a device repairing functional Tricuspid
Regurgitation (fTR) in heart failure patients, to improve quality of life and reduce morbidity.
The Tripair implant is anchored a-traumatically in the right atrium, enabling full retrievability
and intra-procedural efficacy evaluation.
Coramaze Technologies develops the Tripair, a device repairing functional Tricuspid
Regurgitation (fTR) in heart failure patients, to improve quality of life and reduce morbidity.
The Tripair implant is anchored a-traumatically in the right atrium, enabling full retrievability
and intra-procedural efficacy evaluation.
Atraumatic by design, effective by evidence
Transition
Flexible joint allows optimal spacer position
Center Column
Semi-rigid skeleton
supports spacer
Crown
Retrievable a-traumatic
anchoring in right atrium
Spacer
Friendly to native valve,
the spacer balloon fills the coaptation gap
Simple imaging
Intra - procedural
efficacy
Full retrievability
Atraumatic
anchoring
10 mins device
time
Instant relieve
of TR
Short learning
curve
Coramaze Technologies was founded in 2013 as a tech-transfer from Duisburg-Essen university. It is committed to the improvement of structural heart patients’ lives by developing accessible and effective minimally invasive treatments. Our team holds a successful record in R&D of cardiovascular devices, regulatory affairs for global markets and multicenter clinical investigations. The company is currently based in central Israel, directly tapping a network of high-quality medical vendors and talent, while maintaining a presence in Germany.
© 2021 Coramaze Technologies All Rights Reserved // Design by: Studio Kukushka // Build by: Vivir Studio
